JANX Janux Therapeutics, Inc.

neutral track record → $15.46 -0.41 (-2.6%)
Get emailed when JANX changes direction
Mkt Cap $940M 52wk $12.12 - $35.34 Earnings 2026-05-07 46d ago
Insider selling: $343,504,819 sold by 21 insiders (30d)
Est. revisions: +4.7% (2 up, 0 down in 30d)
Backed by structured data (insider trades, analyst ratings, or filings)
Factor Model (net +2.0)

Factor Model

net +2.0 4.5 / 10
Est. Revisions
+0.3
Insider Activity
+0.0
Momentum
+0.0
Analyst Rev.
+1.0
Narrative Gap
+0.0

JANX011 enters human trials targeting immune reset

Watch: Safety and pharmacodynamic data from the Phase 1 cohort over the next 6-12 months will make or break investor conviction. CD19-targeting has a proven safety track record in oncology; the question is whether Janux can replicate that in autoimmune patients without the risk profile of approved CAR-T therapies.

Janux Therapeutics dosed the first patient in its Phase 1 trial of JANX011 on February 17, 2026 — a CD19-targeting drug designed to achieve sustained B cell depletion across blood and tissue. The drug is built on the company's ARM platform and shows pharmacodynamic effects comparable to CAR-T therapies. Initial focus is autoimmune diseases, with potential to expand into hematologic malignancies.

First-in-human dosing marks a major inflection point for a preclinical-stage immunology company. If JANX011 delivers CAR-T-like efficacy in a non-cell therapy format, it could unlock a massive addressable market spanning autoimmune and cancer indications — without the manufacturing complexity that constrains cell therapy adoption.

Evidence

2d ago Barclays down JANX: Overweight → Underweight
7d ago UBS down JANX: Buy → Neutral
9d ago Insider buy by RA CAPITAL MANAGEMENT, L.P. (JANX): $53,700,000
9d ago Insider sell by AVALON VENTURES XI, L.P. (JANX): $77,472,371
9d ago Insider sell by AVALON VENTURES XI, L.P. (JANX): $14,452,394
9d ago Insider sell by AVALON VENTURES XI, L.P. (JANX): $21,153,619
9d ago Insider sell by AVALON VENTURES XI, L.P. (JANX): $10,172,364
9d ago Insider sell by LICHTER JAY (JANX): $82,125,000
4 older signals
9d ago Insider sell by REARDON TIGHE (JANX): $45,043,975
9d ago Insider sell by AVALON VENTURES XI, L.P. (JANX): $82,125,000
9d ago Insider buy by RA CAPITAL MANAGEMENT, L.P. (JANX): $25,342,965
48d ago Janux Therapeutics, Inc. (JANX) Commences Patient Dosing of JANX011 in Autoimmune Trial
Fundamentals & Data ▾
Janux Therapeutics, Inc. Healthcare · Biotechnology
Mkt Cap
$940M
Beta
2.81
52w Range
$12.12 - $35.34
Short Interest
7.7M 18.2%
Days to Cover
6.7 -22%
Technicals downtrend
from 52w Hi
-2.6%
1w return
+1.4%
Insiders
selling 0B / 9S
Analysts
bearish 0 up / 2 down
EPS Estimate
$-0.54 +4.7% 30d 2up / 0dn
Est. Dispersion
56% 9 analysts
Analyst Target
$50 $14 - $100
Options P/C
4.42
Insider Cluster
strong sell 1B / 5S
Fund Convergence
strong D.E. Shaw, Citadel, Two Sigma
Top Holders
D.E. Shaw $22M
Citadel $17M
Two Sigma $1M
Recent Filings & Data
insider trade 78
net selling · $343,504,819 sold · $79,042,965 bought
21 insiders · 78 transactions (30d)
Recent transactions
LICHTER JAY · exercise · $65,951
MEYER ANDREW HOLLMAN · sell · $25,799
CAMPBELL DAVID ALAN · award
CAMPBELL DAVID ALAN · sell · $110,829
WINTER CHARLES M · award
WINTER CHARLES M · sell · $32,966
DIRAIMONDO THOMAS PH.D. · award
DIRAIMONDO THOMAS PH.D. · sell · $34,394
DOBEK MARIA · award
DOBEK MARIA · sell · $20,073
MCIVER ZACHARIAH · award
MCIVER ZACHARIAH · sell · $37,263
DOYLE JANEEN NOEL · award
MEYER ANDREW HOLLMAN · sell · $109,929
MEYER ANDREW HOLLMAN · exercise · $35,296
MEYER ANDREW HOLLMAN · sell · $99,990
MEYER ANDREW HOLLMAN · sell · $500,987
MEYER ANDREW HOLLMAN · exercise · $112,689
DOBMEIER ERIC L · award
BARRETT RONALD W · award
KUNG WINSTON · award
RA CAPITAL MANAGEMENT, L.P. · award
GUJRATHI SHEILA · award
CAPPS VICKIE LYNN · award
HERNDAY NATASHA A · award
SIMSON JAKE · award
MCNULTY ALANA B. · award
DOYLE JANEEN NOEL · award
MEYER ANDREW HOLLMAN · sell · $106,745
MEYER ANDREW HOLLMAN · exercise · $14,032
MEYER ANDREW HOLLMAN · sell · $100,020
MEYER ANDREW HOLLMAN · exercise · $14,036
RA CAPITAL MANAGEMENT, L.P. · buy · $25,342,965
MEYER ANDREW HOLLMAN · sell · $107,174
MEYER ANDREW HOLLMAN · sell · $140,999
CAMPBELL DAVID ALAN · sell · $300,004
MEYER ANDREW HOLLMAN · award
MEYER ANDREW HOLLMAN · sell · $731,785
CAMPBELL DAVID ALAN · award
ROBINSON BYRON C · award
WINTER CHARLES M · award
DIRAIMONDO THOMAS PH.D. · award
DOBEK MARIA · award
MCIVER ZACHARIAH · award
CAMPBELL DAVID ALAN · sell · $1,404,805
MEYER ANDREW HOLLMAN · exercise · $199,985
CAMPBELL DAVID ALAN · sell · $602,700
CAMPBELL DAVID ALAN · sell · $1,289,879
CAMPBELL DAVID ALAN · sell · $1,338,559
RA CAPITAL MANAGEMENT, L.P. · buy · $53,700,000
AVALON VENTURES XI, L.P. · sell · $77,472,371
AVALON VENTURES XI, L.P. · exercise · $222,010
AVALON VENTURES XI, L.P. · sell · $14,452,394
AVALON VENTURES XI, L.P. · exercise · $48,260
MEYER ANDREW HOLLMAN · sell · $2,297,755
MEYER ANDREW HOLLMAN · exercise · $210,500
CAMPBELL DAVID ALAN · sell · $1,157,641
DIRAIMONDO THOMAS PH.D. · sell · $231,716
LICHTER JAY · sell · $178,084
GO WILLIAM M.D., PH.D. · award
AVALON VENTURES XI, L.P. · sell · $21,153,619
AVALON VENTURES XI, L.P. · sell · $10,172,364
AVALON VENTURES XI, L.P. · exercise · $37,838
DOBMEIER ERIC L · award
DOBMEIER ERIC L · award
HERNDAY NATASHA A · award
HERNDAY NATASHA A · award
LICHTER JAY · award
BARRETT RONALD W · award
KUNG WINSTON · award
RA CAPITAL MANAGEMENT, L.P. · award
GUJRATHI SHEILA · award
CAPPS VICKIE LYNN · award
SIMSON JAKE · award
MCNULTY ALANA B. · award
LICHTER JAY · sell · $82,125,000
REARDON TIGHE · sell · $45,043,975
AVALON VENTURES XI, L.P. · sell · $82,125,000
analyst rating 2
Barclays down → Underweight 2d ago
UBS down → Neutral 7d ago
12 signals · latest 2d ago

Get alerted when JANX changes direction

We'll email you when our AI detects a shift — reversals, insider clusters, filing red flags.

All stocks → Our calls → How it works →